Drugs for Squamous Cell Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 177)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Chlorhexidine |
Approved, Vet_approved, Withdrawn |
Phase 4 |
|
55-56-1 |
2713 9552079 |
|
Synonyms:
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
AVAGARD
CHLORHEXIDIN
CHLORHEXIDIN [CZECH]
CHLORHEXIDINE
CHLORHEXIDINUM
CHLORHEXIDINUM [INN-LATIN]
Cloresidina
CLORESIDINA [DCIT]
CLORHEXIDINA
CLORHEXIDINA [INN-SPANISH]
|
Dentisept
EXIDINE
HIBISTAT
Merfen-incolore
N-(4-CHLOROPHENYL)-1-3-(6-{N-[3-(4-CHLOROPHENYL)CARBAMIMIDAMIDOMETHANIMIDOYL]AMINO}HEXYL)CARBAMIMIDAMIDOMETHANIMIDAMIDE
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
NOLVASAN
PERIDEX
STERILON
SUTHOL
SUTHOOOL
|
|
| 2 |
|
Polihexanide |
Approved, Investigational |
Phase 4 |
|
28757-47-3 |
20977 |
|
Synonyms:
Baquacil
Cosmocil
Lavasept
PHMB Polymer
Polihexanide
Polihexanide hydrochloride
Poly(hexamethylene biguanide)
Poly(hexamethylenebiguanide) hydrochloride
Poly(iminocarbonimidoyliminocarbonimidoylimino-1,6-hexanediyl) hydrochloride
|
Polyhexamethylenbiguanid
Polyhexamethylenbiguanide
Polyhexamethylen-biguanide
Polyhexamethylene biguanide
Polyhexamethylene biguanide hydrochloride
Polyhexanide
Vantocil
Vantocil ib OF vantocil
|
|
| 3 |
|
Cidofovir |
Approved |
Phase 4 |
|
113852-37-2 |
60613 |
|
Synonyms:
({[(S)-1-(4-AMINO-2-OXO-1,2-DIHYDROPYRIMIDIN-1-YL)-3-HYDROXYPROPAN-2-YL]OXY}METHYL)PHOSPHONIC ACID
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonate
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-HPMPC
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonate
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-AMINO-2-OXO-1(2H)-PYRIMIDINYL)-1-(HYDROXYMETHYL)ETHOXY]METHYL]PHOSPHONIC ACID
1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine
1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
|
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
CDV
Cidofovir
Cidofovir anhydrous
Cidofovir sodium
Cidofovir, (+-)-isomer
Cidofovir, (R)-isomer
Cidofovir, sodium salt
CIDOFOVIRUM
GS-0504
HPMPC
Vistide
|
|
| 4 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4, 329-65-7 |
838 5816 |
|
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
| 5 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
|
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
| 6 |
|
Biguanides |
|
Phase 4 |
|
|
|
| 7 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
| 8 |
|
Disinfectants |
|
Phase 4 |
|
|
|
| 9 |
|
Anti-Infective Agents, Local |
|
Phase 4 |
|
|
|
| 10 |
|
Chlorhexidine gluconate |
|
Phase 4 |
|
|
|
| 11 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
| 12 |
|
Antibodies |
|
Phase 4 |
|
|
|
| 13 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
| 14 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
| 15 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
| 16 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
| 17 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
| 18 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
| 19 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
| 20 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
| 21 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
| 22 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
| 23 |
|
Mydriatics |
|
Phase 4 |
|
|
|
| 24 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
| 25 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
| 26 |
|
Vaccines |
|
Phase 3 |
|
|
|
| 27 |
|
Erlotinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
|
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
| 28 |
|
Avelumab |
Approved, Investigational |
Phase 2 |
|
1537032-82-8 |
|
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
| 29 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 2 |
|
24280-93-1 |
446541 |
|
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
| 30 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
|
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
| 31 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
|
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
| 32 |
|
Masoprocol |
Approved, Investigational |
Phase 1, Phase 2 |
|
500-38-9, 27686-84-6 |
71398 |
|
Synonyms:
(R*,s*)-4,4'-(2,3-dimethylbutane-1,4-diyl)bispyrocatechol
Acid, meso-nordihydroguaiaretic
Actinex
CHX 100
CHX-100
Dihydronorguaiaretic acid
Erythro-nordihydroguaiaretate
Erythro-nordihydroguaiaretic acid
INSM-18
Masoprocol
Masoprocolum
Meso nordihydroguaiaretic acid
Meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
Meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
Meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
Meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
|
Meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
Meso-b,g-dimethyl-a,delta-bis(3,4-dihydroxyphenyl)butan
Meso-b,g-dimethyl-a,δ-bis(3,4-dihydroxyphenyl)butan
Meso-beta,gamma-dimethyl-alpha,delta-bis(3,4-dihydroxyphenyl)butan
Meso-ndga
Meso-nordihydroguaiaretate
Meso-nordihydroguaiaretic acid
Meso-β,γ-dimethyl-α,δ-bis(3,4-dihydroxyphenyl)butan
NDGA
Nordihydroguaiaretate
Nordihydroguaiaretic acid
Nordihydroguaiaretic acid, (r*,s*)-isomer
Nordihydroguairaretic acid
NSC-4291
NSC-682984
|
|
| 33 |
|
Cianidanol |
Approved, Withdrawn |
Phase 2 |
|
154-23-4 |
9064 |
|
Synonyms:
(-)-Epicatechin
(+)-(2R,3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3’,4’-Tetrahydroxyflavan-3-ol
(+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-3’,4’,5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-Catechin
(+)-Catechin hydrate
(+)-Catechol
(+)-Cianidanol
(+)-Cyanidan-3-ol
(+)-Cyanidanol
(+)-Cyanidanol-3
(+/-)-catechin
(+/-)-catechin hydrate
(2R,3S)-(+)-Catechin
(2R,3S)-Catechin
(2R-trans)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol
3,3',4',5,7-Flavanpentol
Acid, catechinic
Acid, catechuic
Biocatechin
CATECHIN
Catechinate
|
Catechinic acid
Catechuate
Catechuic acid
Catergen
Cianidanol
Cianidanolum
Cianidol
Cyanidanol
Cyanidanol 3
Cyanidanol-3
Cyanidol
D-(+)-Catechin
D-Catechin
D-Catechol
Dexcyanidanol
Epicatechin
KB 53
KB-53
trans-(+)-3,3',4',5,7-Flavanpentol
trans-(+)-3,3’,4’,5,7-Flavanpentol
trans3,3,4,5,7 Pentahydroxyflavane
YK-85 light yellow powder 85
Zyma
|
|
| 34 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
| 35 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
| 36 |
|
Hydroxyurea |
Approved |
Phase 2 |
|
127-07-1 |
3657 |
|
Synonyms:
Biosupressin
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroxyamic acid
Carbamoyl oxime
Carbamyl hydroxamate
Carbamyl hydroxamic acid
Droxia
Droxia®|Hydrea®|hydroxycarbamide|Siklos®|SQ-1089|Xromi®
Hidrix
Hidroxicarbamida
HU
Hydrea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamidum
|
Hydroxycarbamine
Hydroxyharnstoff
Hydroxylurea
HYDROXYUREA
Hydura
Hydurea
Idrossicarbamide
Idrossicarbamide [Dcit]
Litaler
Litalir
N-Carbamoylhydroxylamine
N-HYDROXYUREA
NSC-32065
Oncocarbide
Onco-Carbide
Oxyurea
SIKLOS
SQ-1089
Sterile Urea
Ureaphil
|
|
| 37 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
|
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
| 38 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
|
Synonyms:
|
| 39 |
|
Nelfinavir |
Approved |
Phase 2 |
|
159989-64-7 |
64143 |
|
Synonyms:
1UN
AG1343
Agouron brand OF nelfinavir mesylate
Mesylate, nelfinavir
Monomethane sulfonate, nelfinavir
Nelfinavir
Nelfinavir mesylate
|
Nelfinavir monomethane sulfonate
NFV
NLF
Roche brand OF nelfinavir mesylate
Sulfonate, nelfinavir monomethane
Viracept
|
|
| 40 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
|
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
| 41 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
|
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
| 42 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
| 43 |
|
Fluorouracil |
Approved |
Phase 2 |
|
51-21-8 |
3385 |
|
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
| 44 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
|
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
| 45 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
|
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 46 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
|
Synonyms:
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
CELEBRA
Celebrex
CELECOX
Celecox®|Elyxyb® (DFN-15; oral solution)|Onsenal®|SC-58635|SC58635
Celecoxib
Célécoxib
|
Celecoxibum
Celocoxib
DFN15
DFN-15
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
SC-58635
|
|
| 47 |
|
Panitumumab |
Approved, Investigational |
Phase 2 |
|
339177-26-3 |
|
|
Synonyms:
ABX-EGF
ABX-EGF|ABX-EGF Mab|Vectibix®
E7.6.3
|
L01XC08
PANITUMUMAB
VECTIBIX
|
|
| 48 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
|
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
| 49 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
|
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
| 50 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
56-84-8 |
5960 |
|
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
Interventional clinical trials:
(show top 50)
(show all 262)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women During a Two Dose 9-valent HPV Vaccination Series |
Unknown status |
NCT04311528 |
Phase 4 |
|
| 2 |
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients |
Completed |
NCT02624349 |
Phase 4 |
Quadravalent human papillomavirus vaccine |
| 3 |
Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine |
Completed |
NCT01740245 |
Phase 4 |
|
| 4 |
Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students |
Completed |
NCT04459221 |
Phase 4 |
Gardasil 9, 9-Valent Intramuscular Suspension |
| 5 |
Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." |
Completed |
NCT00205374 |
Phase 4 |
Cidofovir;Placebo |
| 6 |
Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) |
Recruiting |
NCT03350698 |
Phase 4 |
|
| 7 |
Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. |
Recruiting |
NCT04232917 |
Phase 4 |
2LPAPI®;Placebo |
| 8 |
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose |
Recruiting |
NCT03943875 |
Phase 4 |
|
| 9 |
Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live |
Active, not recruiting |
NCT05279248 |
Phase 4 |
|
| 10 |
Study on the Immunogenicity and Safety of Co-immunization With Recombinant Human Papillomavirus 16/18 Bivalent Vaccine and Hepatitis E Vaccine |
Active, not recruiting |
NCT05415345 |
Phase 4 |
|
| 11 |
A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV |
Active, not recruiting |
NCT04274153 |
Phase 4 |
|
| 12 |
Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) |
Active, not recruiting |
NCT03391921 |
Phase 4 |
|
| 13 |
Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures |
Not yet recruiting |
NCT05294640 |
Phase 4 |
0.9% Bacteriostatic Local Anesthetic Injection;1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection |
| 14 |
Immunogenicity of 9-valent HPV Vaccine in Immunocompromised Children and Adolescents |
Not yet recruiting |
NCT05439083 |
Phase 4 |
|
| 15 |
Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") |
Terminated |
NCT00747461 |
Phase 4 |
|
| 16 |
The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) |
Withdrawn |
NCT04183738 |
Phase 4 |
NRTIs;Darunavir;Ritonavir;Dolutegravir |
| 17 |
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV |
Withdrawn |
NCT01663558 |
Phase 4 |
imiquimod |
| 18 |
A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years |
Unknown status |
NCT02733068 |
Phase 3 |
|
| 19 |
Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place |
Unknown status |
NCT03296397 |
Phase 3 |
|
| 20 |
Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). |
Unknown status |
NCT02382900 |
Phase 3 |
|
| 21 |
Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children |
Unknown status |
NCT01995721 |
Phase 3 |
|
| 22 |
Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result |
Completed |
NCT00964210 |
Phase 3 |
Licensed quadrivalent HPV vaccine, Gardasil |
| 23 |
Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study |
Completed |
NCT00090220 |
Phase 3 |
|
| 24 |
Quadrivalent and Bivalent Human Papilloma Virus Vaccines in the Treatment of Common Recalcitrant Warts |
Completed |
NCT05383625 |
Phase 3 |
Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine;Bivalent Human Papilloma Virus Vaccine;Saline |
| 25 |
A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men |
Completed |
NCT01862874 |
Phase 3 |
|
| 26 |
A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys |
Completed |
NCT02576054 |
Phase 3 |
|
| 27 |
A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men |
Completed |
NCT02114385 |
Phase 3 |
|
| 28 |
An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients |
Completed |
NCT03525210 |
Phase 3 |
|
| 29 |
Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis |
Completed |
NCT01375868 |
Phase 3 |
|
| 30 |
The Effects of Probiotic Against Reducing Abundance of Human Papilloma Virus (HPV) in Women |
Recruiting |
NCT05316064 |
Phase 2, Phase 3 |
|
| 31 |
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study |
Active, not recruiting |
NCT02135419 |
Phase 3 |
imiquimod;fluorouracil |
| 32 |
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls |
Active, not recruiting |
NCT02834637 |
Phase 3 |
bivalent HPV vaccine;nonavalent HPV vaccine |
| 33 |
Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions |
Not yet recruiting |
NCT03289260 |
Phase 3 |
Imiquimod 5% cream;Placebo cream |
| 34 |
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV |
Not yet recruiting |
NCT05495906 |
Phase 3 |
|
| 35 |
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis |
Withdrawn |
NCT01058317 |
Phase 2, Phase 3 |
Propranolol |
| 36 |
Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx |
Unknown status |
NCT00002454 |
Phase 2 |
|
| 37 |
Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection |
Unknown status |
NCT03351855 |
Phase 1, Phase 2 |
|
| 38 |
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand |
Unknown status |
NCT03302858 |
Phase 2 |
|
| 39 |
Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load |
Unknown status |
NCT01654822 |
Phase 2 |
topical application cervical spray;topical spray on the cervix |
| 40 |
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial |
Unknown status |
NCT02555800 |
Phase 2 |
Bevacizumab;Cidofovir |
| 41 |
A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
Completed |
NCT00492089 |
Phase 2 |
bevacizumab;placebo |
| 42 |
A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma |
Completed |
NCT00101348 |
Phase 1, Phase 2 |
erlotinib hydrochloride |
| 43 |
A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis |
Completed |
NCT02859454 |
Phase 2 |
Avelumab |
| 44 |
A Phase II Study of M7824 in Subjects With Recurrent Respiratory Papillomatosis |
Completed |
NCT03707587 |
Phase 2 |
M7824 |
| 45 |
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis |
Completed |
NCT01806675 |
Phase 1, Phase 2 |
18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2 |
| 46 |
A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women |
Completed |
NCT00520598 |
Phase 2 |
Comparator: V505 formulation 2 |
| 47 |
A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options |
Completed |
NCT02128126 |
Phase 1, Phase 2 |
ISA101/ISA101b |
| 48 |
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery |
Completed |
NCT02827838 |
Phase 2 |
|
| 49 |
Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy |
Completed |
NCT00005941 |
Phase 2 |
cyclosporine;fludarabine phosphate;mycophenolate mofetil |
| 50 |
A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins |
Completed |
NCT00002916 |
Phase 2 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|
podophyllin
|
PODOPHYLLIN PWDR
|
Cochrane evidence based reviews: papilloma
|
